CONCLUSIONS
fragile myeloma
There was a trend that the oral ICd or Id regimen exhibited good effectiveness and tolerability during the initial treatment of fragile patients with NDMM. Although no robust conclusions and comparison could be drawn with ICd and Id regimens regarding the small number of patients, a favorable outcome was observed in this trial. Moreove, the convenience and tolerability might make ixazomib effective in the long‐term treatment. To conclude, the promising clinical activity warrants further study. As an ongoing prospective study, we are expanding the samples to further study the effectiveness and safety of ICd followed by ixazomib as maintenance in elderly and fragile myeloma, as well as whether it is superior to the Id regimen.